Cellular tumor antigen p53–E3 ubiquitin-protein ligase Mdm2 protein–protein interface (p53–MDM2 PPI)

The p53–MDM2 protein–protein interface is a critical regulatory node that governs the stability and tumor-suppressive activity of the p53 transcription factor. Under normal physiological conditions, the E3 ubiquitin ligase MDM2 binds to the N-terminal transactivation domain of p53, inhibiting its transcriptional function and targeting it for proteasomal degradation [1.3.1, 1.3.5]. In many human malignancies, particularly those retaining wild-type p53, MDM2 is frequently overexpressed or its gene is amplified, leading to the constitutive inactivation of p53 and promoting uncontrolled cell growth [1.3.1, 1.4.4]. Therapeutic targeting of this interface involves small-molecule inhibitors, such as Nutlins and their clinical-grade derivatives, which occupy the hydrophobic p53-binding pocket on MDM2 [1.3.1, 1.4.3]. By sterically hindering the interaction, these drugs stabilize p53, allowing it to accumulate in the nucleus and activate downstream genes involved in cell cycle arrest, senescence, and apoptosis [1.3.2, 1.4.5]. While these inhibitors show significant promise in MDM2-amplified tumors like liposarcoma and certain leukemias, their clinical utility is often limited by dose-dependent hematological toxicities and the potential for the emergence of resistant p53 mutations [1.1.1, 1.2.4].

Other names

p53-MDM2 interactionMDM2-p53 complexTP53-MDM2 interfaceMDM2-p53 binding sitep53-MDM2 binding interface

Small-molecule inhibitors competitively bind to the hydrophobic p53-binding pocket of MDM2, mimicking the key p53 residues (Phe19, Trp23, and Leu26). This blockade prevents MDM2 from ubiquitinating p53 and targeting it for degradation, resulting in p53 stabilization, nuclear accumulation, and the induction of p53-dependent pathways such as cell cycle arrest and apoptosis [1.3.1, 1.4.4, 1.4.5].